A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse

Veterinary Immunology and Immunopathology

Volumn 123, Issue 3-4, 2008, Pages 230-239

  El Garch, H ^a   Minke, J M ^a   Rehder, J ^a   Richard, S ^a   Edlund Toulemonde, C ^a   Dinic, S ^a   Andreoni, C ^a   Audonnet, J C ^a   Nordgren, R ^a   Juillard, V ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

ALVAC ; Anti vector immunity; Equine; WNV immunity

Indexed keywords

ALVAC; GAMMA INTERFERON; GENE PRODUCT; NEUTRALIZING ANTIBODY; RECOMBITEK; VIRUS VECTOR; WEST NILE VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HORSE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; MALE; NONHUMAN; TRANSGENE; VIRUS IMMUNITY; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HORSE DISEASES; HORSES; IMMUNIZATION, SECONDARY; INTERFERON TYPE II; MALE; NEUTRALIZATION TESTS; STATISTICS, NONPARAMETRIC; VACCINATION; VIRAL VACCINES; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

CANARYPOX VIRUS; EQUIDAE; WEST NILE VIRUS;

EID: 43649093448     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2008.02.002     Document Type: Article

References (39)

1. Berencsi K., Gyulai Z., Gonczol E., Pincus S., Cox W.I., Michelson S., Kari L., Meric C., Cadoz M., Zahradnik J., Starr S., and Plotkin S. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J. Infect. Dis. 183 (2001) 1171-1179
2. Boehme K.W., and Compton T. Innate sensing of viruses by toll-like receptors. J. Virol. 78 (2004) 7867-7873
3. Breathnach C.C., Rudersdorf R., and Lunn D.P. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Vet. Immunol. Immunopathol. 98 (2004) 127-136
4. Buckley A., Dawson A., Moss S.R., Hinsley S.A., Bellamy P.E., and Gould E.A. Serological evidence of West Nile virus, Usutu virus and Sindbis virus infection of birds in the UK. J. Gen. Virol. 84 (2003) 2807-2817
5. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., Tang A., Chen M., Huang L., Harris V., Freed D.C., Wilson K.A., Dubey S., Zhu D.M., Nawrocki D., Mach H., Troutman R., Isopi L., Williams D., Hurni W., Xu Z., Smith J.G., Wang S., Liu X., Guan L., Long R., Trigona W., Heidecker G.J., Perry H.C., Persaud N., Toner T.J., Su Q., Liang X., Youil R., Chastain M., Bett A.J., Volkin D.B., Emini E.A., and Shiver J.W. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77 (2003) 6305-6313
6. Daly J.M., Newton J.R., and Mumford J.A. Current perspectives on control of equine influenza. Vet. Res. 35 (2004) 411-423
7. Diamond M.S., Shrestha B., Marri A., Mahan D., and Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77 (2003) 2578-2586
8. Diamond M.S., Shrestha B., Mehlhop E., Sitati E., and Engle M. Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol. 16 (2003) 259-278
9. Doherty P.C. Cytotoxic T cell effector and memory function in viral immunity. Curr. Top. Microbiol. Immunol. 206 (1996) 1-14
10. Edlund Toulemonde C., Daly J., Sindle T., Guigal P.M., Audonnet J.C., and Minke J.M. Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom. Vet. Rec. 156 (2005) 367-371
11. Engle M.J., and Diamond M.S. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J. Virol. 77 (2003) 12941-12949
12. Franchini G., Gurunathan S., Baglyos L., Plotkin S., and Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev. Vaccines 3 (2004) S75-S88
13. Gould L.H., and Fikrig E. West Nile virus: a growing concern?. J. Clin. Invest. 113 (2004) 1102-1107
14. Grosenbaugh D.A., Backus C.S., Karaca K., Minke J.M., and Nordgren R.M. The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine. Vet. Ther. 5 (2004) 251-257
15. Hartikka J., Sawdey M., Cornefert-Jensen F., Margalith M., Barnhart K., Nolasco M., Vahlsing H.L., Meek J., Marquet M., Hobart P., Norman J., and Manthorpe M. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum. Gene Ther. 7 (1996) 1205-1217
16. Hayes E.B., and Gubler D.J. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu. Rev. Med. 57 (2006) 181-194
17. Ignatius R., Marovich M., Mehlhop E., Villamide L., Mahnke K., Cox W.I., Isdell F., Frankel S.S., Mascola J.R., Steinman R.M., and Pope M. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J. Virol. 74 (2000) 11329-11338
18. Juillard V., Villefroy P., Godfrin D., Pavirani A., Venet A., and Guillet J.G. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur. J. Immunol. 25 (1995) 3467-3473
19. Kamath A.T., Sheasby C.E., and Tough D.F. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J. Immunol. 174 (2005) 767-776
20. Kanesa-thasan N., Smucny J.J., Hoke C.H., Marks D.H., Konishi E., Kurane I., Tang D.B., Vaughn D.W., Mason P.W., and Shope R.E. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 19 (2000) 483-491
21. Karaca K., Bowen R., Austgen L.E., Teehee M., Siger L., Grosenbaugh D., Loosemore L., Audonnet J.C., Nordgren R., and Minke J.M. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge. Vaccine 23 (2005) 3808-3813
22. Kundig T.M., Kalberer C.P., Hengartner H., and Zinkernagel R.M. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 11 (1993) 1154-1158
23. Lauterbach H., Ried C., Epstein A.L., Marconi P., and Brocker T. Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. J. Gen. Virol. 86 (2005) 2401-2410
24. Minke J.M., Siger L., Karaca K., Austgen L., Gordy P., Bowen R., Renshaw R.W., Loosmore S., Audonnet J.C., and Nordgren B. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch. Virol. Suppl. 18 (2004) 221-230
25. Minke J.M., Fischer L., Baudu P., Guigal P.M., Sindle T., Mumford J.A., and Audonnet J.C. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Vet. Immunol. Immunopathol. 111 (2006) 47-57
26. Minke J.M., Toulemonde C.E., Coupier H., Guigal P.M., Dinic S., Sindle T., Jessett D., Black L., Bublot M., Pardo M.C., and Audonnet J.C. Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge. Am. J. Vet. Res. 68 (2007) 213-219
27. Nacsa J., Radaelli A., Edghill-Smith Y., Venzon D., Tsai W.P., Morghen Cde G., Panicali D., Tartaglia J., and Franchini G. Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques. Vaccine 22 (2004) 597-606
28. O'Neill T., Kydd J.H., Allen G.P., Wattrang E., Mumford J.A., and Hannant D. Determination of equid herpesvirus 1-specific, CD8+, cytotoxic T lymphocyte precursor frequencies in ponies. Vet. Immunol. Immunopathol. 70 (1999) 43-54
29. Paillot R., Daly J.M., Juillard V., Minke J.M., Hannant D., and Kydd J.H. Equine interferon gamma synthesis in lymphocytes after in vivo infection and in vitro stimulation with EHV-1. Vaccine 23 (2005) 4541-4551
30. Paillot R., Ellis S.A., Daly J.M., Audonnet J.C., Minke J.M., Davis-Poynter N., Hannant D., and Kydd J.H. Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection. Vaccine 24 (2006) 1490-1500
31. Pardo M.C., Bauman J.E., and Mackowiak M. Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins. Am. J. Vet. Res. 58 (1997) 833-836
32. Poulet H., Brunet S., Boularand C., Guiot A.L., Leroy V., Tartaglia J., Minke J., Audonnet J.C., and Desmettre P. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia. Vet. Rec. 153 (2003) 141-145
33. Ramirez J.C., Gherardi M.M., Rodriguez D., and Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J. Virol. 74 (2000) 7651-7655
34. Santra S., Schmitz J.E., Kuroda M.J., Lifton M.A., Nickerson C.E., Lord C.I., Pal R., Franchini G., and Letvin N.L. Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys. J. Immunol. 168 (2002) 1847-1853
35. Sharpe S., Polyanskaya N., Dennis M., Sutter G., Hanke T., Erfle V., Hirsch V., and Cranage M. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J. Gen. Virol. 82 (2001) 2215-2223
36. Shrestha B., and Diamond M.S. Role of CD8+ T cells in control of West Nile virus infection. J. Virol. 78 (2004) 8312-8321
37. Shrestha B., Samuel M.A., and Diamond M.S. CD8+ T cells require perforin to clear West Nile virus from infected neurons. J. Virol. 80 (2006) 119-129
38. Shrestha B., Wang T., Samuel M.A., Whitby K., Craft J., Fikrig E., and Diamond M.S. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J. Virol. 80 (2006) 5338-5348
39. Siger L., Bowen R.A., Karaca K., Murray M.J., Gordy P.W., Loosmore S.M., Audonnet J.C., Nordgren R.M., and Minke J.M. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. Am. J. Vet. Res. 65 (2004) 1459-1462